Kara Johnson, MD
Pulmonary Disease · Fargo, NDNPI 1578708228
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,681 of the $4,306 with a category attached, or 62.3%. Intuitive Surgical accounts for 86.5% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $3,620, more than ten times the $182 reported in 2019.
Across 31 payments — averaging $138.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$153
- Insmed, Inc.$97
- United Therapeutics Corporation$74
- Sanofi-aventis U.S. LLC$57
- Regeneron Healthcare Solutions, Inc.$36
- plus $162 from 7 others
Across 1 payment — averaging $179.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$180
What the payments were for
- Travel & lodging$1,01324%
- Food & beverage$61214%
- Education$2,68162%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $3,726 |
| AstraZeneca | 2 | $153 |
| Insmed, Inc. | 6 | $97 |
| United Therapeutics Corporation | 2 | $74 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Amgen | 1 | $28 |
| Johnson & Johnson | 1 | $28 |
| Baxter Healthcare | 1 | $26 |
| CSL Behring | 2 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Sanofi | 1 | $19 |
| Veran Medical Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,582
- FASENRA$125
How this compares
$4,306 in reported general payments places this provider in the 60th percentile of 31 pulmonary disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 185 | $167,906 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $59,068 |
| Spiriva RespimatTiotropium Bromide | 64 | $52,297 |
| Dupixent SyringeDupilumab | 11 | $40,680 |
| Incruse ElliptaUmeclidinium Bromide | 77 | $36,686 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $33,878 |
| Spiriva HandihalerTiotropium Bromide | 47 | $33,157 |
| DuleraMometasone/Formoterol | 62 | $22,574 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $22,235 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $20,745 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 113 | $19,235 |
| Arnuity ElliptaFluticasone Furoate | 39 | $13,694 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 42 | $13,196 |
| Ventolin HfaAlbuterol Sulfate | 88 | $7,852 |
| Serevent DiskusSalmeterol Xinafoate | 16 | $6,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $24 | $73,042108 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $153 | $39,41672 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 31 pulmonary disease providers in North Dakota.
Other pulmonary disease in Fargo
- Seema KhoslaFargo$43K
- Venkatkiran KanchustambhamFargo$14K
- Michael TalalaevFargo$8K
- Muhammad Asad FaruqiFargo$8K
- Craig BackousFargo$7K
- Weston BowkerFargo$4K
- Praveen JinnurFargo$3K
- Karol KremensFargo$2K
- Ajay AggarwalFargo$560
- Namratta GhatehordeFargo$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.